{"id":60074,"date":"2024-02-28T06:32:14","date_gmt":"2024-02-28T06:32:14","guid":{"rendered":"https:\/\/medsname.com\/mozep\/"},"modified":"2026-04-30T10:23:51","modified_gmt":"2026-04-30T10:23:51","slug":"mozep","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/mozep\/","title":{"rendered":"Mozep"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Snel antwoord<\/h3>\n

Mozep (Pimozide 2 mg) is a butyrophenone first-generation antipsychotic. Modern use is restricted to refractory Tourette syndrome (with motor and vocal tics) and treatment-resistant delusional disorder. Strong dose-dependent QT prolongation and torsades risk \u2014 pre-treatment ECG mandatory.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Mozep at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 werkdagen levertermijn of wij sturen kosteloos opnieuw \u2014 en komt in aanmerking voor ons klantenloyaliteitsprogramma<\/a>. Wereldwijde verzending is beschikbaar naar de meeste bestemmingen.<\/p>\n

What Mozep is and how it works<\/h2>\n

Mozep is a pimozide tablet supplied by Sun Pharma. Available strengths: 2 mg<\/strong>. Pimozide is a butyrophenone (related to haloperidol) with selective D2 antagonism, modest 5-HT2A antagonism, and meaningful calcium-channel blockade \u2014 the latter is the basis for the QT-prolonging effect that limits its use.<\/p>\n

Modern indications: refractory Tourette syndrome (FDA approval), monosymptomatic delusional disorder (e.g. delusions of parasitosis, somatic delusions), and rare schizophrenia cases unresponsive to other agents.<\/p>\n

Indicaties en dosering<\/h2>\n\n\n\n\n\n\n\n\n\n
Indicatie<\/th>\nStartdosering<\/th>\nStreefdosering<\/th>\nMaximaal<\/th>\n<\/tr>\n<\/thead>\n
Tourette syndrome (adult)<\/td>\n1 mg HS<\/td>\n1\u201310 mg\/day<\/td>\n0.2 mg\/kg or 10 mg<\/td>\n<\/tr>\n
Tourette syndrome (paediatric \u2265 12 y)<\/td>\n0.05 mg\/kg HS<\/td>\n0.2 mg\/kg\/day<\/td>\n0.2 mg\/kg or 10 mg<\/td>\n<\/tr>\n
Monosymptomatic delusional disorder<\/td>\n2 mg eenmaal daags<\/td>\n2\u20134 mg\/dag<\/td>\n\u2014<\/td>\n<\/tr>\n
Schizophrenia (refractory)<\/td>\n1 mg BID<\/td>\n2\u201310 mg\/day<\/td>\n20 mg<\/td>\n<\/tr>\n
CYP2D6 poor metaboliser \/ inhibitor<\/td>\nhalveer de dosis<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Belangrijke veiligheidsoverwegingen<\/h2>\n
\nFDA black-box \u2014 dementiegerelateerde psychose<\/strong><\/p>\n

Alle atypische antipsychotica dragen een FDA black-box waarschuwing voor verhoogde sterfte (voornamelijk cardiovasculair en infectieus) bij gebruik voor gedragsstoornissen bij oudere volwassenen met dementie. Atypische antipsychotica zijn niet goedgekeurd voor dementiegerelateerde psychose of agitatie.<\/strong>. Gebruik bij deze populatie is off-label, als laatste redmiddel, tijdelijk en vereist een expliciet risico-voordeel gesprek.<\/p>\n<\/div>\n

\nMandatory pre-treatment ECG and absolute contraindications<\/strong><\/p>\n

Pimozide carries a strong dose-dependent QT signal. Pre-treatment ECG required; check QTc at every dose increase; stop if QTc > 500 ms or rises > 60 ms from baseline.<\/strong> Absolute contraindications: known long QT, congenital arrhythmia syndrome, recent MI, uncompensated heart failure, hypokalaemia\/hypomagnesaemia (correct before starting), concurrent QT-prolonging drugs, and concurrent strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit juice \u2014 all raise pimozide levels and the QT signal substantially).<\/p>\n<\/div>\n

\nCYP3A4 + CYP2D6 dual substrate<\/strong><\/p>\n

Pimozide is metabolised by both CYP3A4 and CYP2D6. Strong inhibitors of either enzyme raise levels and amplify QT risk. Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) and strong CYP3A4 inhibitors are absolute contraindications.<\/p>\n<\/div>\n

\nEPS, TD, and acute dystonia<\/strong><\/p>\n

As a butyrophenone, pimozide produces meaningful EPS, akathisia, acute dystonia (particularly in young men), and cumulative tardive dyskinesia. Anticholinergic adjunct (procyclidine, benztropine) sometimes used acutely.<\/p>\n<\/div>\n

Veelvoorkomende bijwerkingen<\/h2>\n